Here are four points:
1. Cantel Medical will pay $13.5 million in cash consideration.
2. NAMSA’s Sterility Assurance Monitoring Products manufactures biological and chemical indicators which are used to monitor the effectiveness of sterilization processes.
3. NAMSA’s sterility assurance products will be integrated into the Crosstex product portfolio and reported in Cantel Medical’s healthcare disposables segment.
4. The transaction is expected to close in the third quarter of fiscal year 2016.
More articles on GI/endoscopy:
DuPage Medical Group acquires Midwest Digestive Disease Specialists: 3 things to know
8 must-reads on colonoscopy
5 things to know about office visit costs prior to screening colonoscopy
